These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 2159837

  • 1. Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center.
    Joss RA, Bürki K, Dalquen P, Schatzmann E, Leyvraz S, Cavalli F, Ludwig C, Siegenthaler P, Alberto P, Stahel R.
    Cancer; 1990 Jun 01; 65(11):2426-34. PubMed ID: 2159837
    [Abstract] [Full Text] [Related]

  • 2. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer.
    Klastersky J, Sculier JP, Ries F, Dabouis G, Libert P, Schmerber J, Thiriaux J, Berchier MC, Bureau G, Van Cutsem O.
    Lung Cancer; 1994 Dec 01; 11(5-6):373-84. PubMed ID: 7704494
    [Abstract] [Full Text] [Related]

  • 3. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
    Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR.
    Ann Oncol; 1996 Oct 01; 7(8):821-6. PubMed ID: 8922196
    [Abstract] [Full Text] [Related]

  • 4. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
    Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Fernandez C, Ribelles N, Culubret M.
    Cancer; 1990 Apr 15; 65(8):1692-9. PubMed ID: 2156597
    [Abstract] [Full Text] [Related]

  • 5. [Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer].
    Hayashi Y, Kato M, Matsuura T, Yamada Y, Adachi S, Ito G, Yamamoto K, Takeuchi T.
    Gan To Kagaku Ryoho; 1990 Aug 15; 17(8 Pt 1):1455-60. PubMed ID: 2167632
    [Abstract] [Full Text] [Related]

  • 6. Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques).
    Riggi M, Ruffie P, Voisin S, Monnet I, de Cremoux H, Saltiel JC, Martin M, Vergne L, Huet J, Cvitkovic E.
    Eur J Cancer; 1991 Aug 15; 27(10):1238-42. PubMed ID: 1659842
    [Abstract] [Full Text] [Related]

  • 7. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
    Fujii M, Kiura K, Okabe K, Toki H, Kimura M.
    Gan To Kagaku Ryoho; 1987 Sep 15; 14(9):2676-81. PubMed ID: 2820312
    [Abstract] [Full Text] [Related]

  • 8. Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer.
    Stockler M, Raghavan D, McCaughan BC, Grygiel J, McNeil E, Gianoutsos P, Lee JH.
    Med J Aust; 1992 May 18; 156(10):698-700. PubMed ID: 1377770
    [Abstract] [Full Text] [Related]

  • 9. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.
    Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Saijo N.
    Eur J Cancer; 1991 May 18; 27(5):571-5. PubMed ID: 1647183
    [Abstract] [Full Text] [Related]

  • 10. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F, Sica G, De Filippis S, Rosselli M, Saggio G, Guerriero G, Pompili P, Rea S.
    Anticancer Res; 2000 May 18; 20(3B):1985-90. PubMed ID: 10928138
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
    Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M, Ogawara M.
    J Clin Oncol; 1991 Apr 18; 9(4):606-13. PubMed ID: 1648597
    [Abstract] [Full Text] [Related]

  • 12. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
    Takifuji N, Fukuoka M, Negoro S, Takada M, Kusunoki Y, Matsui K, Masuda N, Ryu S, Sakai N, Kubota K.
    Gan To Kagaku Ryoho; 1990 Mar 18; 17(3 Pt 2):429-34. PubMed ID: 2157364
    [Abstract] [Full Text] [Related]

  • 13. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.
    Luedke DW, Einhorn L, Omura GA, Sarma PR, Bartolucci AA, Birch R, Greco FA.
    J Clin Oncol; 1990 May 18; 8(5):886-91. PubMed ID: 2159054
    [Abstract] [Full Text] [Related]

  • 14. Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study.
    Miller TP, Vance RB, Ahmann FR, Rodney SR.
    Cancer Treat Rep; 1986 Sep 18; 70(9):1101-4. PubMed ID: 3527409
    [Abstract] [Full Text] [Related]

  • 15. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N.
    Oncology (Williston Park); 2001 Jan 18; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [Abstract] [Full Text] [Related]

  • 16. Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.
    Vansteenkiste J, Vandebroek J, Mariën S, Roex L, Bertrand P, Bockaert J, De Beukelaar T, Deman R, De Muynck P, Ulrichts H.
    Lung Cancer; 1995 Dec 18; 13(3):295-303. PubMed ID: 8719069
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
    Furuse K, Kubota K, Kawahara M, Kodama N, Ogawara M, Akira M, Nakajima S, Takada M, Kusunoki Y, Negoro S.
    J Clin Oncol; 1995 Apr 18; 13(4):869-75. PubMed ID: 7707113
    [Abstract] [Full Text] [Related]

  • 18. Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer. A phase II study.
    Fukuoka M, Negoro S, Masuda N, Kusunoki Y, Matsui K, Ryu S, Takifuji N, Kudoh S, Takada M.
    Am J Clin Oncol; 1992 Feb 18; 15(1):18-22. PubMed ID: 1312768
    [Abstract] [Full Text] [Related]

  • 19. Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.
    Kris MG, Gralla RJ, Wertheim MS, Kelsen DP, O'Connell JP, Burke MT, Fiore JJ, Cibas IR, Heelan RT.
    Cancer Treat Rep; 1986 Sep 18; 70(9):1091-6. PubMed ID: 3527408
    [Abstract] [Full Text] [Related]

  • 20. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
    Takada M, Fukuoka M, Ariyoshi Y, Furuse K, Niitani H, Ota K, Motomiya M, Hasegawa K, Tominaga K, Kuriyama T.
    Cancer Chemother Pharmacol; 1992 Sep 18; 31(3):182-6. PubMed ID: 1281446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.